A lower quote does not settle what a compound is or why it is proposed. First ask for the ingredient, the pharmacy preparing it, and the personal medical reason for using it. Then ask about cost. A useful comparison holds these questions apart so an attractive price does not quietly become the explanation for the whole care plan.
Know what is being prepared
A compounder makes a drug instead of supplying a ready-made approved product. A doctor, a registered facility, or a pharmacist can act as that compounder. Compounded drugs lack FDA approval in the position checked November 3, 2026. They reach the market without FDA’s prior review of safety, quality, or benefit. The reason FDA describes for choosing a compound is an unmet medical need with the approved product. Ask what that need is in the plan being discussed.
- Ask what specific need the proposed compound is meant to address. Request an answer tied to your assessment.
- Ask who actually prepares and sends it. A service's name on the website may not identify the pharmacy.
- Keep the compound name on the quote. Avoid comparing a broad compounded-care offer with a differently described approved product.
Source notes
The source below supports the point above, within its stated limits.
FDA · why medicines are compoundedFDA · limits of compounded-drug reviewCheck copy restrictions before the price
The rules checked November 3, 2026 limit making copies on a regular basis or in large amounts. The rule concerns drugs already on the market. There is an exception when the prescriber decides a change in the compound makes a significant difference for the person named on the prescription. A lower bill does not supply that personal difference. Adding a vitamin may still leave a product within the copy rule, according to FDA. Ask what change matters for your care rather than treating the price as the reason.
- Ask the clinician (doctor, physician assistant, or nurse practitioner) what makes the compound different for your own medical need. Request that explanation in everyday language.
- If a service points to a shortage, ask which current FDA listing it means. A gap on a local pharmacy shelf does not establish that national status.
- Ask how the service will respond if the proposed compound cannot be supplied. Keep any payment terms for that situation in writing.
Source notes
The source below supports the point above, within its stated limits.
FDA · shortage and copy policiesFDA · the national shortage listRead the dated supply position
As checked November 3, 2026, FDA listed neither tirzepatide nor semaglutide as in shortage. They were also absent from the raw-ingredient list for outsourcing facilities. These are businesses registered with FDA. They make medicines in batches, often supplying hospitals and clinics. Ask whether the proposed drug comes from that type of facility or a pharmacy making it for a named person. FDA had proposed keeping both drugs, along with liraglutide, off that facility list. The proposal was not a final decision. If an ingredient is missing from that list, ask which rule would let the facility use it. This is a question about permission to prepare the drug, as well as price. These facts do not supply a blanket answer for all compounds or all peptides.
- Get a fresh answer about the named preparation before committing to recurring charges. Save the date and the source given.
- Ask what is included in a bundle and what is billed separately. Ask about payment, medical need, and the rules as separate questions.
- For the newer policy concerning selected peptides, read the separate policy page. Its narrow scope does not answer every compounding question.
- If the service cannot answer the compound or sourcing question, leave that line open in the comparison. Ask for the missing detail in writing. The next useful step is to identify the actual proposed medicine before trying to settle its total cost.
Source notes
The source below supports the point above, within its stated limits.
FDA · shortage and copy policiesFederal Register · proposed facility ingredient decisionFDA · outsourcing ingredient list